Sanofi to Invest $476 Million into New Singapore Vaccine Production Center

Sanofi announced on April 12, 2021 that it will invest €400 million (US$476 million) over the course of five years to develop a vaccine production center in Singapore.

In collaboration with the Singapore Economic Development Board (EDB), the new site will supply the Asian region and will include multiple fully digitalized modules for the production of three to four vaccines simultaneously, Sanofi said in a company press release. Additionally, the facility will have the capacity to utilize several vaccine manufacturing technology platforms based on different cell types for the production of a specific vaccine in a faster timeframe to meet public health needs.

The facility is currently in its design phase with construction expected to begin in the third quarter of 2021. It is set to be fully operational in the first quarter of 2026 if all qualifications and validations of the first manufactured vaccine have been completed.

“As a major healthcare player, it’s our responsibility to act and to meet the unprecedented growing demands for vaccines. By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics,” said Thomas Triomphe, executive vice-president and global head of Sanofi Pasteur, in the press release. “We are very pleased by the strong collaboration with the Singapore Economic Development Board to achieve this exciting milestone.”

“Sanofi’s decision to locate its first-in-Asia digitally-enabled vaccine production center in Singapore, to supply markets in the region and beyond, is an endorsement of Singapore’s position as a leading center for advanced manufacturing,” added Beh Swan Gin, chairman, EDB, in the press release. “EDB will continue to promote digitalization, automation, and innovation to transform the manufacturing sector and create good jobs for Singaporeans.”

Source: Sanofi